Clinical Trials Logo

Renal Insufficiency clinical trials

View clinical trials related to Renal Insufficiency.

Filter by:

NCT ID: NCT01443429 Completed - Renal Impairment Clinical Trials

A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment

Start date: August 2011
Phase: Phase 1
Study type: Interventional

The PK and safety profiles to be examined following a single oral administration of TRK-100STP (120 μg) under fasting conditions to patients with renal impairment and to subjects with normal renal function.

NCT ID: NCT01442259 Completed - Clinical trials for or Severe Renal Impairment

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

Start date: January 2011
Phase: Phase 1
Study type: Interventional

The aim of this study was to characterize the pharmacokinetics and safety of AFQ056 in subjects with a different degree of renal impairment.

NCT ID: NCT01440881 Completed - Renal Failure Clinical Trials

Does Nesiritide Provide Renal Protection

Start date: April 2010
Phase: Phase 2
Study type: Interventional

This project evaluates whether nesiritide, human recombinant brain natriuretic peptide, confers renal protection during cardiovascular surgery by attenuating the inflammatory response.

NCT ID: NCT01432535 Completed - Renal Insufficiency Clinical Trials

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

Start date: November 2011
Phase: Phase 1
Study type: Interventional

This study will compare the pharmacokinetics of a single dose of peginterferon alfa-2b (Sylatron®) in healthy participants to that in participants with moderate to severe impairment of kidney function.

NCT ID: NCT01429038 Completed - Kidney Failure Clinical Trials

Mesenchymal Stem Cells After Renal or Liver Transplantation

Start date: February 1, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The immune system of a patient can attack the liver or the kidney received from a donor (organ rejection). This can be prevented by treating these patients long-life with immunosuppressive drugs. Unfortunately, these drugs lead to numerous side effects and fail to prevent the rejection occurring months later after the transplantation (chronic rejection). Recently, it has been shown that a particular type of cells present in the bone marrow, namely Mesenchymal Stem Cells (MSC), when injected to a patient, suppress its immune system and increase success rates of blood cells transplantation. This outcome opens doors to investigate the potential of these cells to provide a valuable tool for improving solid organ transplantation without the need of high concentration of immunosuppressive drugs. The present project aims at evaluating the safety and tolerability of MSC administration after liver or kidney transplantation.

NCT ID: NCT01424176 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Dexpramipexole Renal PK Study

Start date: July 2011
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, single-dose, PK and safety study in subjects with various stages of renal impairment.

NCT ID: NCT01423955 Completed - Renal Failure Clinical Trials

Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery

EPRICS
Start date: October 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the potential of erythropoietin in reducing risk and degree of acute kidney injury after cardiac surgery.

NCT ID: NCT01419041 Completed - Renal Impairment Clinical Trials

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

Start date: November 2011
Phase: Phase 1
Study type: Interventional

The present study is being conducted to evaluate whether or not severe renal impairment has an effect on crizotinib Pharmacokinetics.

NCT ID: NCT01418677 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

Start date: October 2011
Phase: Phase 1
Study type: Interventional

This is an open-label non-randomized study in subjects with advanced or metastatic solid tumors who are no longer responding to available therapy. HALAVEN will be administered to subjects on Days 1 and 8 of a 21-day cycle.

NCT ID: NCT01407874 Completed - Arthritis Clinical Trials

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

Start date: September 2011
Phase: Phase 2
Study type: Interventional

To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency.